A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia

Journal of Psychopharmacology

Volumn 25, Issue 5, 2011, Pages 685-697

  Gopal, S ^a   Vijapurkar, U ^a   Lim, P ^a   Morozova, M ^b   Eerdekens, M ^c   Hough, D ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Atypical antipsychotic; long acting injectable; open label extension; paliperidone palmitate; safety; schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO;

ADULT; AGED; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INSOMNIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL BEHAVIOR; SYMPTOM; TREATMENT DURATION; TREMOR; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; RECURRENCE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS;

EID: 79955379088     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110372817     Document Type: Article

References (35)

1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 ; 154: 672-676 (Pubitemid 19154942)
2. Bloch Y, Mendlovic S, Strupinsky S, Altshuler A, Fennig S, Ratzoni G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?. J Clin Psychiatry. 2001 ; 62: 855-859 (Pubitemid 33131171)
3. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007 ; 30: 437-452 (Pubitemid 47284561)
4. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005 ; 15: 111-117 (Pubitemid 39574406)
5. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs. 2007 ; 21: 441-448 (Pubitemid 46849180)
6. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003 ; 64: 1250-1257
7. Gaebel W, Bergmans P, de Arce R, et al. P03-21 Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable versus quetiapine: Randomized, long-term, open-label, clinical trial results (ConstaTRE) 17th EPA Congress, Lisbon, Portugal, January 2009. Abstract book European Psychiatry. 2009 ; 24: S1020 - S1020
8. Glazer WM, Byerly MJ. Tactics and technologies to manage nonadherence in patients with schizophrenia. Curr Psychiatry Rep. 2008 ; 10: 359-369
9. Guy W AIMS. Abnormal Involuntary Movement Scale. ECDEU Assessment for Psychopharmacology. Rev. Ed. Rockville, Maryland: National Institute of Mental Health ; 1976 :
10. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs. 2006 ; 20: 293-301
11. Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J. 1973 ; 1: 633-637
12. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010 ; 116: 107-117
13. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33: 1022-1031
14. Johnson DA, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psychiatr Scand. 1979 ; 59: 525-528 (Pubitemid 9191722)
15. Johnstone EC, Geddes J. How high is the relapse rate in schizophrenia?. Acta Psychiatrica Scand. 1994 ; 89: 6-10 (Pubitemid 24199706)
16. Kane JM. Treatment adherence and long-term outcomes. CNS Spectr. 2007 ; 12: 21-26 (Pubitemid 350099581)
17. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998 ; 8: 55-66
18. Kane JM, Eerdekens M, Lindenmayer JP, Keith , Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003 ; 160: 1125-1132 (Pubitemid 41070972)
19. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry. 2007 ; 191: 131-139 (Pubitemid 47204533)
20. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2009 ; 13: 635-647
21. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry. 2004 ; 19: 219-225 (Pubitemid 38766136)
22. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008 ; 69: 790-799 (Pubitemid 351838688)
23. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 ; 373: 31-41
24. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry. 2004 ; 65: 1084-1089
25. Marinis TD, Saleem PT, Glue P, et al. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry. 2007 ; 40: 257-263 (Pubitemid 350232817)
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 ; 28: 412-419 (Pubitemid 15018832)
27. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006 ; 67 (suppl 5). 15-18 (Pubitemid 43837697)
28. Moller HJ. Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry. 2005 ; 20: 379-385
29. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol. 2005 ; 20: 121-130 (Pubitemid 40571509)
30. Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry. 1982 ; 43: 195-196 (Pubitemid 12117414)
31. Rainer MK. Risperidone long-acting injection: a review of its long-term safety and efficacy. Neuropsychiatr Dis Treat. 2008 ; 4: 919-927
32. Samtani M, Sliwa JK, Haskins JT, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: Pharmacokinetic rationale based on modeling and simulation. J Pharm Pract. 2009b ; 22: 216-217
33. Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care. 2005 ; 11: S235 - S241
34. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970 ; 212: 11-19
35. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004 ; 19: 241-249 (Pubitemid 38901653)